Tandem Diabetes Care is a medical devices business based in the US. Tandem Diabetes Care shares (TNDM) are listed on the NASDAQ and all prices are listed in US Dollars. Tandem Diabetes Care employs 2,400 staff and has a trailing 12-month revenue of around $770 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $40.65 |
|---|---|
| 52-week range | $13.82 - $53.69 |
| 50-day moving average | $45.72 |
| 200-day moving average | $30.77 |
| Wall St. target price | $51.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.16 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $40.65 from 2024-07-25
| 1 week (2024-07-19) | -6.89% |
|---|---|
| 1 month (2024-06-27) | 0.54% |
| 3 months (2024-04-26) | 15.35% |
| 6 months (2024-01-26) | 77.43% |
| 1 year (2023-07-27) | 17.55% |
|---|---|
| 2 years (2022-07-27) | -37.29% |
| 3 years (2021-07-27) | 102.05 |
| 5 years (2019-07-26) | 62.96 |
| Revenue TTM | $770 million |
|---|---|
| Gross profit TTM | $413 million |
| Return on assets TTM | -9.7% |
| Return on equity TTM | -48.63% |
| Profit margin | -18.37% |
| Book value | $3.77 |
| Market Capitalization | $2.8 billion |
TTM: trailing 12 months
We're not expecting Tandem Diabetes Care to pay a dividend over the next 12 months.
Tandem Diabetes Care's shares were split on a 1:10 basis on 9 October 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tandem Diabetes Care shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tandem Diabetes Care shares which in turn could have impacted Tandem Diabetes Care's share price.
Over the last 12 months, Tandem Diabetes Care's shares have ranged in value from as little as $13.82 up to $53.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tandem Diabetes Care's is 1.287. This would suggest that Tandem Diabetes Care's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Tandem Diabetes Care, Inc. , a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.